11. First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC). Issue 3 (22nd March 2023) Authors: Autio, Karen A; Higano, Celestia S; Nordquist, Luke; Appleman, Leonard J; Zhang, Tian; Zhu, Xin-Hua; Babiker, Hani; Vogelzang, Nicholas J; Prasad, Sandip M; Schweizer, Michael T; Madan, Ravi A; Billotte, Stephane; Cavazos, Nora; Bogg, Orlaith; Li, Ray; Chan, Kam; Cho, Helen; Kaneda, Megan; Wang, ... Journal: Journal for immunotherapy of cancer Issue: Volume 11:Issue 3(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. Introduction to the Yale Precision Medicine Tumor Board. Issue 1 (January 2018) Authors: Cecchini, Michael; Walther, Zenta; Sklar, Jeffrey L; Bindra, Ranjit S; Petrylak, Daniel P; Eder, Joseph P; Goldberg, Sarah B Journal: Lancet oncology Issue: Volume 19:Issue 1(2018) Page Start: 19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer. (6th November 2014) Authors: Xiao, Yuanyuan; Rabe, Christina; Kowanetz, Marcin; Powles, Thomas; Vogelzang, Nicholas J; Petrylak, Daniel P; Loriot, Yohann; Denker, Mitchell; Nakamura, Rin; Wu, Qun J; Sumiyoshi, Teiko; Boyd, Zachary; Teng, Siew-leng M; Shen, Xiaodong; Fine, Gregg; Chen, Daniel S; Hegde, Priti S Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. Issue 8 (17th August 2022) Authors: Fizazi, Karim; Retz, Margitta; Petrylak, Daniel P; Goh, Jeffrey C; Perez-Gracia, Jose; Lacombe, Louis; Zschäbitz, Stefanie; Burotto, Mauricio; Mahammedi, Hakim; Gravis, Gwenaelle; Bastos, Diogo Assed; McCune, Steven L; Vázquez Limón, Juan Carlos; Kwan, Edmond M; Castellano, Daniel; Fléchon, Aude;... Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 8(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Issue 10109 (18th November 2017) Authors: Petrylak, Daniel P; de Wit, Ronald; Chi, Kim N; Drakaki, Alexandra; Sternberg, Cora N; Nishiyama, Hiroyuki; Castellano, Daniel; Hussain, Syed; Fléchon, Aude; Bamias, Aristotelis; Yu, Evan Y; van der Heijden, Michiel S; Matsubara, Nobuaki; Alekseev, Boris; Necchi, Andrea; Géczi, Lajos; Ou, Yen-Chu... Journal: Lancet Issue: Volume 390:Issue 10109(2017) Page Start: 2266 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Issue 1 (January 2020) Authors: Petrylak, Daniel P; de Wit, Ronald; Chi, Kim N; Drakaki, Alexandra; Sternberg, Cora N; Nishiyama, Hiroyuki; Castellano, Daniel; Hussain, Syed A; Fléchon, Aude; Bamias, Aristotelis; Yu, Evan Y; van der Heijden, Michiel S; Matsubara, Nobuaki; Alekseev, Boris; Necchi, Andrea; Géczi, Lajos; Ou, Yen-C... Journal: Lancet oncology Issue: Volume 21:Issue 1(2020) Page Start: 105 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Issue 8 (August 2019) Authors: Herbst, Roy S; Arkenau, Hendrik-Tobias; Santana-Davila, Rafael; Calvo, Emiliano; Paz-Ares, Luis; Cassier, Philippe A; Bendell, Johanna; Penel, Nicolas; Krebs, Matthew G; Martin-Liberal, Juan; Isambert, Nicolas; Soriano, Andres; Wermke, Martin; Cultrera, Jennifer; Gao, Ling; Widau, Ryan C; Mi, Gu;... Journal: Lancet oncology Issue: Volume 20:Issue 8(2019) Page Start: 1109 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens. (25th February 2021) Authors: Kibel, Adam S; Inman, Brant A; Pachynski, Russell K; Vu, Tuyen; Sheikh, Nadeem A; Petrylak, Daniel P Journal: Journal of the National Cancer Institute Issue: Volume 114:Number 2(2022) Page Start: 310 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes. Issue 1 (January 2018) Authors: Cecchini, Michael; Walther, Zenta; Sklar, Jeffrey L; Bindra, Ranjit S; Petrylak, Daniel P; Eder, Joseph P; Goldberg, Sarah B Journal: Lancet oncology Issue: Volume 19:Issue 1(2018) Page Start: 23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗